NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Read More
Author: Selina McKee
EU nod for AZ’ COPD maintenance therapy
The triple combination therapy Trixeo Aerosphere cut the rate of moderate or severe exacerbations compared with dual-combination therapies in clinical trials
Read More
Winners shine bright at PharmaTimes Awards
Meet the winners of the 2020 PharmaTimes Marketer of the Year, Communications Awards and Sales Awards
Read More
NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The recommendations are positive for a select population of patients with CLL
Read More
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
